Mirion Technologies Inc

MIR

Equity

ISIN null / Valor 114384757

New York Stock Exchange, Inc (2026-06-26)

USD 18.45-0.11%

Mirion Technologies Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Mirion Technologies Inc. is a company specializing in radiation detection, measurement, and monitoring solutions, serving a variety of industrial markets. Established through a series of mergers between 1950 and 2004, Mirion was officially incorporated in 2005 and has since been organized into several key divisions, including Radiation Monitoring, Health Physics, Sensing, Imaging, and Dosimetry Services. The company has expanded its capabilities in the healthcare sector, particularly in occupational dosimetry, medical imaging, nuclear medicine, radiation therapy, and diagnostic imaging quality assurance, leading to the formation of the Mirion Medical group in 2022. Mirion's product offerings are designed to support critical applications in safety, security, and healthcare, providing essential tools for radiation protection and management.

Summarized from source with an LLMView SourceSector: Finance

Revenue

Q1 2026 revenue was $257.6 million, up 27.5% vs. $202.0 million in Q1 2025 (product $197.0M; service $60.6M).

Profitability and margins

GAAP net loss for Q1 2026 was $3.4 million (loss per share $0.01) versus GAAP net income of $0.4 million in Q1 2025. Adjusted EBITDA was $54.3 million, a 16.3% increase from $46.7 million a year earlier; Adjusted EBITDA margin was 21.1% vs. 23.1% in Q1 2025.

Earnings per share (Adjusted)

GAAP loss per share (basic/diluted) was $(0.01) in Q1 2026. Adjusted EPS was $0.10 for Q1 2026, unchanged from $0.10 in Q1 2025; the current-period adjusted EPS calculation was updated to include stock‑based compensation.

Order activity and M&A contribution

Q1 2026 orders were $241 million excluding the Paragon & Certrec acquisitions (up 19% vs. $203M a year ago). Including Paragon and Certrec, orders were $288 million (up 42% YoY). Management cited strong Nuclear Power demand and Paragon’s contribution in its first full quarter.

2026 guidance

Mirion reaffirmed guidance for full-year 2026 on total revenue growth (~22%–24%), Organic Revenue growth (~5%–7%), Adjusted EBITDA ($285M–$300M; margin ~25%–26%), and Adjusted Free Cash Flow ($155M–$175M). Adjusted EPS was revised to ~$0.48–$0.55 (previously $0.50–$0.57) to reflect a special one-time CEO retention grant of performance-vesting stock options.

Cash flow and balance sheet

Cash and cash equivalents were $397.9 million at March 31, 2026 (total assets $3,535.9M). Net cash provided by operating activities in Q1 was $18.9 million; purchases of property, plant and equipment were $9.5 million. Convertible debt stood at $755.6 million and non‑current debt was $443.5 million.

Management commentary

CEO Thomas Logan highlighted accelerating Nuclear Power momentum, record capital spending by plant operators, and ongoing integration and synergies from Paragon as drivers of the quarter’s performance and backlog growth.

Summarized from source with an LLMView Source

Key figures

-14.3%1Y

137%3Y

82.0%5Y

Performance

54.3%1Y

44.8%3Y

45.4%5Y

Volatility